• Artículo
      Icon

      Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib 

      Rodríguez Gil, Alfonso; Escamilla Gómez, Virginia; Nufer, Melanie; Andújar Sánchez, Félix; Lopes Ramos, Teresa; Bejarano García, José Antonio; Caballero Velázquez, Teresa; Villadiego Luque, Francisco Javier; Pérez Simón, José Antonio (Nature Publishing Group, 2022)
      Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as ...